Hospitals protest Genentech's changes to distribution of top cancer drugs
On October 1, biotech firm Genentech began a major change in the distribution process for their 3 top cancer drugs: Avastin (bevacizumab), Herceptin (trastuzumab), and Rituxan (rituximab). Distribution of the drugs to hospitals and clinics now will be restricted to authorized specialty distributors.
Reaction by hospitals and pharmacy executives to this change has been swift because of perceived significantly increased costs as well as delays in therapy for patients. According to a letter from the Hematology/Oncology Pharmacy Association (HOPA) to Genentech CEO Ian Clark, this decision “will have a direct and negative impact on our cancer center operations and have adverse effects on patient care.”
HOPA points out that a major consequence will be the loss of wholesaler rebates, increasing the financial burden on care providers and ultimately on patients. It will also affect their delivery systems, meaning that delays in getting a drug to the clinic will be more likely. As the HOPA letter states, “Drugs ordered on one day will not arrive in time for early appointments the next day.”
Genentech sees this issue very differently. The company “is committed to patient safety, to protecting the integrity of our medicines as they move through the supply chain,” said Charlotte Arnold, the associate director of corporate relations for Genentech. She added that the company is also committed “to ensuring patients and healthcare professionals are able to access our medicines when they need them.”
Another objection voiced by HOPA was the increased costs in packaging that will result from the products being shipped by courier, necessitating more complexly packed items. Such packaging will impact facilities with limited space, as well as waste management for all facilities in regard to disposal of the packaging materials. Genentech, however, cites that these cancer medicines “require special storage and handling.”
The change in the distribution process for the 3 drugs began on October 1, 2014.
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
What Payers Need to Know As Retail Pharmacies Move Into Primary Care
September 6th 2023Healthcare beyond the doors of the doctor’s office has the potential to offer more care to more people. But payers need to think about how to ensure that care is consistent. Regardless of the setting, care decisions must be based on evidence-based content and supported with strong patient education.
Read More
